Skip to main content
. 2020 Nov 13;21(22):8560. doi: 10.3390/ijms21228560

Figure 5.

Figure 5

Systemic treatment with Pam3CSK4 and Pam2CSK4 attenuates imiquimod-induced skin inflammation. Shaved back skin of wild-type (WT) mice were topically treated with imiquimod for 5 consecutive days. Wild-type mice were injected with 50 g Pam3CSK4 and 50 g Pam2CSK4 (PAM) or PBS intravenously two days before, on the same day, and two days after imiquimod application. (A) The phenotypical manifestation of back skin induced by imiquimod application at day 5. (B) Disease severity during imiquimod treatment. Clinical scores for disease severity were calculated daily using a scoring system based on the clinical psoriasis area and severity index. Data are presented as mean ± SEM of three independent experiments (n = 9 for each group). * p < 0.05 versus WT mice with imiquimod application. (C) Messenger RNA levels of the indicated cytokines and Foxp-3 were determined by quantitative RT-PCR. Values are presented as mean ± SEM (n = 9). * p < 0.05, ** p < 0.01.